Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03362658 · ClinicalTrials.gov registry record

Novel MRI Biomarkers for Monitoring Disease Progression in ALS

A clinical trial of Amyotrophic Lateral Sclerosis and Motor Neuron Disease, sponsored by University of Alberta.

Recruiting
Registry status
700
Enrollment target
9
Study locations

NCT03362658 is a study of Amyotrophic Lateral Sclerosis and Motor Neuron Disease that is actively recruiting participants, run by University of Alberta. The registered enrollment target is 700 participants, below the 891-participant average among 102 other Amyotrophic Lateral Sclerosis trials with a reported enrollment target (21% lower). The trial reports 9 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03362658, a study of Amyotrophic Lateral Sclerosis and Motor Neuron Disease, is actively recruiting participants, sponsored by University of Alberta.

RECRUITING
Registry status
700 participants
Enrollment target
9
Study locations

Study Summary

Routine MRI is normal in motor neuron diseases such as ALS. However, advanced MRI techniques can provide an objective measure of degeneration (a "biomarker") by examining brain structure, wiring, chemistry, and function. We will develop and evaluate novel MRI techniques that could improve our understanding of ALS and provide a means to diagnose it sooner and monitor its progression. Importantly, we expect these techniques to improve how new drugs are tested, which may lead to the more rapid discovery of a treatment for ALS. Each participant will have 3 MRI scans over a period of 8 months, along with neurological and cognitive evaluations. Study visits will take 2 - 3 hours. MRI is a safe technique that does not involve radiation.

Conditions Studied

Amyotrophic Lateral Sclerosis Motor Neuron Disease

Study Locations (9)

Alberta

  • University of Calgary / Heritage Medical Research Clinic - Calgary
  • University of Alberta - Edmonton

Ontario

  • Western University / London Health Sciences Centre - London
  • University of Toronto / Sunnybrook Health Sciences Centre - Toronto

Quebec

  • McGill University / Montreal Neurological Institute and Hospital - Montreal
  • Laval University - Québec

Florida

  • University of Miami - Miami

Utah

  • University of Utah - Salt Lake City

British Columbia

  • University of British Columbia / GF Strong Rehab Centre - Vancouver

Trial Details

FieldValue
Enrollment Target 700 participants
Start Date 2016-10
Est. Completion 2025-12-31

Sponsor

University of Alberta

19 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03362658

The ClinicalTrials.gov registry entry for NCT03362658 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 700 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 891-participant average among 102 other Amyotrophic Lateral Sclerosis trials with a reported enrollment target (21% lower). The listed sponsor is University of Alberta, which has 19 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Amyotrophic Lateral Sclerosis appearing as the primary indexed condition, and to 0 interventions.

NCT03362658 reports 9 study locations spanning 6 distinct geographic areas - top geographies include Alberta, Ontario, Quebec.

Frequently Asked Questions

What is clinical trial NCT03362658 about?

NCT03362658 is a clinical study titled "Novel MRI Biomarkers for Monitoring Disease Progression in ALS". Routine MRI is normal in motor neuron diseases such as ALS. However, advanced MRI techniques can provide an objective measure of degeneration (a "biomarker") by examining brain structure, wiring, chemistry, and function. We will develop and evaluate novel MRI techniques that could improve our unders...

What is the current status of trial NCT03362658?

This trial is currently recruiting. The enrollment target is 700 participants. The study started on 2016-10. Estimated completion is 2025-12-31.

What conditions does trial NCT03362658 study?

This clinical trial studies the following conditions: Amyotrophic Lateral Sclerosis, Motor Neuron Disease.

Who is sponsoring clinical trial NCT03362658?

This trial is sponsored by University of Alberta, which has 19 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03362658 being conducted?

This trial has 9 study locations across Florida, Utah, Alberta, British Columbia, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Amyotrophic Lateral Sclerosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Amyotrophic Lateral Sclerosis

All registered trials for this condition

Motor Neuron Disease

All registered trials for this condition

Florida

All trials with a study site in Florida

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.